Literature DB >> 21121067

Effect of high glucose levels on the calcification of vascular smooth muscle cells by inducing osteoblastic differentiation and intracellular calcium deposition via BMP-2/Cbfα-1 pathway.

Fang Liu1, Hui Zhong, Jing-yuan Liang, Ping Fu, Zhi-juan Luo, Li Zhou, Rong Gou, Jun Huang.   

Abstract

In this paper, we investigate the effect and the possible mechanism of high glucose levels on the calcification of human aortic smooth muscle cells (HASMCs). HASMCs were divided into four groups: normal glucose group (NG), osmolality control group (OC), high glucose group (HG, HASMCs culture medium containing 30 mmol/L glucose), and high glucose plus recombinant human Noggin protein (bone morphogenetic protein-2 (BMP-2) antagonist) group (HN). The mRNA levels and the protein expressions of BMP-2 and core binding factor alpha-1 (Cbfα-1) were measured by real-time quantitative polymerase chain reaction (PCR) and Western blot. After induced by 10 mmol/L β-glycerol phosphoric acid, cells were harvested for assessments of alkaline phosphatase (ALP) activities at Days 1, 2, and 3, and intracellular calcium contents at Days 7 and 14, respectively. High glucose levels increased the mRNA levels and the protein expressions of BMP-2 and Cbfα-1 (P<0.05). The expression of Cbfα-1 was partially blocked by Noggin protein (P<0.05), while BMP-2 was not (P>0.05). After being induced by β-glycerol phosphoric acid, high glucose levels increased the ALP activity [(48.63±1.03) vs. (41.42±2.28) U/mg protein, Day 3; P<0.05] and the intracellular calcium content [(2.76±0.09) vs. (1.75±0.07) μmol/mg protein, Day 14; P<0.05] in a time-dependent manner when compared with the NG group, while the ALP activity could not be blocked by Noggin protein [(48.63±1.03) vs. (47.37±0.97) U/mg protein, Day 3; P>0.05]. These results show that high glucose levels can evoke the calcification of HASMCs by inducing osteoblastic trans-differentiation and intracellular calcium deposition via the BMP-2/Cbfα-1 pathway, which can be partially blocked by Noggin protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121067      PMCID: PMC2997397          DOI: 10.1631/jzus.B1000119

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  22 in total

Review 1.  Signal transduction by the TGF-beta superfamily.

Authors:  Liliana Attisano; Jeffrey L Wrana
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

2.  Endoglin, a TGF-beta receptor-associated protein, is expressed by smooth muscle cells in human atherosclerotic plaques.

Authors:  B A Conley; J D Smith; M Guerrero-Esteo; C Bernabeu; C P Vary
Journal:  Atherosclerosis       Date:  2000-12       Impact factor: 5.162

3.  Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques.

Authors:  C R Dhore; J P Cleutjens; E Lutgens; K B Cleutjens; P P Geusens; P J Kitslaar; J H Tordoir; H M Spronk; C Vermeer; M J Daemen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-12       Impact factor: 8.311

4.  Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers.

Authors:  S A Steitz; M Y Speer; G Curinga; H Y Yang; P Haynes; R Aebersold; T Schinke; G Karsenty; C M Giachelli
Journal:  Circ Res       Date:  2001-12-07       Impact factor: 17.367

5.  Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.

Authors:  Neal X Chen; Kalisha D O'Neill; Danxia Duan; Sharon M Moe
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

6.  Runx2 is a common target of transforming growth factor beta1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal precursor cell line C2C12.

Authors:  K S Lee; H J Kim; Q L Li; X Z Chi; C Ueta; T Komori; J M Wozney; E G Kim; J Y Choi; H M Ryoo; S C Bae
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

7.  High-density lipoprotein regulates calcification of vascular cells.

Authors:  Farhad Parhami; Benjamin Basseri; Jason Hwang; Yin Tintut; Linda L Demer
Journal:  Circ Res       Date:  2002-10-04       Impact factor: 17.367

8.  Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages.

Authors:  Atsushi Shioi; Miwako Katagi; Yasuhisa Okuno; Katsuhito Mori; Shuichi Jono; Hidenori Koyama; Yoshiki Nishizawa
Journal:  Circ Res       Date:  2002-07-12       Impact factor: 17.367

9.  Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.

Authors:  Sharon M Moe; Danxia Duan; Brian P Doehle; Kalisha D O'Neill; Neal X Chen
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

10.  RNA interference for noggin enhances the biological activity of bone morphogenetic proteins in vivo and in vitro.

Authors:  Kazushi Takayama; Akinobu Suzuki; Tomoya Manaka; Susumu Taguchi; Yusuke Hashimoto; Yuuki Imai; Shigeyuki Wakitani; Kunio Takaoka
Journal:  J Bone Miner Metab       Date:  2009-02-28       Impact factor: 2.626

View more
  13 in total

Review 1.  Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes.

Authors:  L Bessueille; D Magne
Journal:  Cell Mol Life Sci       Date:  2015-03-08       Impact factor: 9.261

2.  C-type natriuretic peptide inhibiting vascular calcification might involve decreasing bone morphogenic protein 2 and osteopontin levels.

Authors:  Jing-Jing Chen; Jing Zhang; Yan Cai; Ye-Bo Zhou; Ge-Bo Wen; Chao-Shu Tang; Yong-Fen Qi; Zhi-Sheng Jiang
Journal:  Mol Cell Biochem       Date:  2014-04-08       Impact factor: 3.396

3.  Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus.

Authors:  Jack M Heath; Yong Sun; Kaiyu Yuan; Wayne E Bradley; Silvio Litovsky; Louis J Dell'Italia; John C Chatham; Hui Wu; Yabing Chen
Journal:  Circ Res       Date:  2014-02-13       Impact factor: 17.367

4.  The bone morphogenic protein inhibitor, noggin, reduces glycemia and vascular inflammation in db/db mice.

Authors:  Mitsuhisa Koga; Niels Engberding; Anna E Dikalova; Kyung Hwa Chang; Bonnie Seidel-Rogol; James S Long; Bernard Lassègue; Hanjoong Jo; Kathy K Griendling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-06-28       Impact factor: 4.733

5.  High mobility group box 1 (HMGB1) mediates high-glucose-induced calcification in vascular smooth muscle cells of saphenous veins.

Authors:  Yongyi Wang; Jianggui Shan; Wengang Yang; Hui Zheng; Song Xue
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

6.  High-glucose levels and elastin degradation products accelerate osteogenesis in vascular smooth muscle cells.

Authors:  Aditi Sinha; Naren R Vyavahare
Journal:  Diab Vasc Dis Res       Date:  2013-06-10       Impact factor: 3.291

Review 7.  A review of the effect of diet on cardiovascular calcification.

Authors:  Rachel Nicoll; John McLaren Howard; Michael Y Henein
Journal:  Int J Mol Sci       Date:  2015-04-21       Impact factor: 5.923

8.  Lifestyle including dietary habits and changes in coronary artery calcium score: a retrospective cohort study.

Authors:  EunSun Cheong; Jong-Young Lee; Sung Ho Lee; Jin-Ho Kang; Bum-Soo Kim; Byung Jin Kim; Ki-Chul Sung
Journal:  Clin Hypertens       Date:  2016-01-28

Review 9.  Interplay between BMPs and Reactive Oxygen Species in Cell Signaling and Pathology.

Authors:  Cristina Sánchez-de-Diego; José Antonio Valer; Carolina Pimenta-Lopes; José Luis Rosa; Francesc Ventura
Journal:  Biomolecules       Date:  2019-09-26

10.  The Association between Changes in Coronary Artery Calcium Scores, Dietary Intake, Physical Activity, and Depression Symptoms among the Population of Gaza Strip, Palestine.

Authors:  Abdelrazeq Beram; Kate Zinszer; Nouf Bamuhair; Samer Abuzerr; Kamal Jabre; Huda Gharbia; Abdel Hamid El Bilbeisi; Awny Ubeid; Waliu Jawula Salisu
Journal:  Ethiop J Health Sci       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.